Orchard Therapeutics Plc (ORTX) Tops Q2 EPS by 196c

Orchard Therapeutics Plc (NASDAQ: ORTX) reported Q2 EPS of ($0.07), $1.96 better than the analyst estimate of ($2.03). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $5.33 million.

For earnings history and earnings-related data on Orchard Therapeutics Plc (ORTX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation